GlassScriptPhysician profile
Zackary Wages
NPI 1740869817
$1,599.82
in general payments reported to CMS, 2019-2025
22 companies · $1,269 in 2025
The $1,269 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $331 · 2025: $1,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,599.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $242.35 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $224.44 | 2024-2025 | |
| Glaxosmithkline, LLC. | $167.55 | 2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $149.93 | 2025 | Caplyta |
| Lilly USA, LLC | $135.29 | 2024-2025 | Zepbound, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $115.02 | 2024-2025 | Jardiance, Tradjenta, Synjardy |
| Astrazeneca Pharmaceuticals LP | $88.44 | 2024-2025 | Breztri, Airsupra, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.06 | 2024-2025 | Xifaxan |
| Pfizer INC. | $61.14 | 2024-2025 | |
| Astellas Pharma US INC | $53.23 | 2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $46.66 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $43.89 | 2025 | Auvelity |
| Cranial Technologies, INC | $32.81 | 2024-2025 | Doc Band |
| Amgen INC. | $28.50 | 2025 | Otezla, Repatha |
| Exact Sciences Corporation | $22.46 | 2025 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $21.42 | 2025 | Flucelvax, Fluad |
| Collegium Pharmaceutical, INC. | $19.54 | 2025 | Jornay Pm |
| Atricure, INC. | $17.88 | 2025 | Atriclip Laa Exclusion System |
| Bayer Healthcare Pharmaceuticals INC. | $16.28 | 2024 | |
| Corium, LLC | $16.11 | 2025 | Azstarys |
| Dynavax Technologies Corporation | $15.03 | 2025 | Heplisav-B |
| Merck Sharp & Dohme LLC | $13.79 | 2025 | Capvaxive, Enflonsia, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zackary Wages listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.